Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 4:30 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1225–1248 of 1,451 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Primary Parkinsonism Clear all

Conditions: Deep Brain Stimulation
Interventions: SIS System; Device
Lead sponsor: Surgical Information Sciences Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Parkinson's Disease
Interventions: Not listed
Lead sponsor: 23andMe, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 13,576 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2021
U.S. locations: 1
States / cities: Mountain View, California

Conditions: Parkinsonian Syndrome
Interventions: [123I]ß CIT and SPECT imaging; Drug
Lead sponsor: Institute for Neurodegenerative Disorders; Other
Eligibility: 22 Years and older
Enrollment: 232 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2013
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Parkinson's Disease, Freezing of Gait, Cognitive Ability, General
Interventions: Droxidopa, sugar pill; Drug
Lead sponsor: Henry Ford Health System; Other
Eligibility: 30 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: Chicago, Illinois • West Bloomfield, Michigan

Conditions: Parkinson's Disease
Interventions: Physical exercise intervention, Cognitive exercise intervention, Health education; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 40 Years to 89 Years
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Parkinson Disease
Interventions: LY03003; Drug
Lead sponsor: Luye Pharma Group Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 2
States / cities: Hallandale, Florida • Atlanta, Georgia

Conditions: Parkinson Disease
Interventions: Microbiome specimens in stool; Diagnostic Test
Lead sponsor: Corewell Health West; Other
Eligibility: Not listed
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Grand Rapids, Michigan

Conditions: Parkinson's Disease
Interventions: Mesenchymal Stem Cells, Placebo; Drug
Lead sponsor: Mya Schiess; Other
Eligibility: 50 Years to 79 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Amyotrophic Lateral Sclerosis (ALS), Parkinson's Disease (PD)
Interventions: The MIND diet; Behavioral
Lead sponsor: The University of Tennessee, Knoxville; Other
Eligibility: 30 Years and older
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 3
States / cities: Elizabethton, Tennessee • Knoxville, Tennessee

Conditions: Advanced Parkinson's Disease
Interventions: Optimized Medical Treatment, Levodopa-Carbidopa Intestinal Gel, Nasojejunal (NJ) tube, Percutaneous endoscopic gastrostomy with a jejunal (PEG-J) tube; Drug · Device
Lead sponsor: AbbVie; Industry
Eligibility: 30 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 8
States / cities: Fountain Valley, California • Boca Raton, Florida • Jacksonville, Florida + 5 more

Conditions: Idiopathic Parkinson Disease
Interventions: Tozadenant; Drug
Lead sponsor: Biotie Therapies Inc.; Industry
Eligibility: 30 Years to 80 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 31
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Long Beach, California + 25 more

Conditions: Parkinson Disease
Interventions: CoQ10, GPI 1485; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 30 Years and older
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Parkinson Disease
Interventions: PD Drivers Using AV Technologies On-road; Other
Lead sponsor: University of Florida; Other
Eligibility: 35 Years to 85 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Parkinson's Disease
Interventions: Light Therapy Device; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 40 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Parkinson's Disease
Interventions: ExAblate Transcranial System; Device
Lead sponsor: InSightec; Industry
Eligibility: 30 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Parkinson's Disease, Obsessive Compulsive Disorder, Dystonia, Essential Tremor, Epilepsy
Interventions: Stereotactic brain procedures; Device
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 6 Years to 90 Years
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Predicted Tauopathies, Including, Progressive Supranuclear Palsy, Frontotemporal Dementia With Parkinsonism Linked to Chromosome 17, Corticobasal Degeneration Syndrome, Progressive Nonfluent Aphasia
Interventions: davunetide (AL-108, NAP), Placebo nasal spray; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 40 Years to 85 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Voice Quality and Voice Loudness Associated With Parkinson's Disease
Interventions: Singing Therapy; Other
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 30 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Parkinson Disease
Interventions: Standard of care + Mediterranean diet (intervention), Standard of care (control); Other
Lead sponsor: University of Florida; Other
Eligibility: 40 Years to 85 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Parkinson's Disease
Interventions: AAV-GAD Low Dose, AAV-GAD High Dose, Sham Surgery; Genetic · Procedure
Lead sponsor: MeiraGTx, LLC; Industry
Eligibility: 25 Years to 85 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 6
States / cities: New Haven, Connecticut • West Bloomfield, Michigan • New York, New York + 2 more

Conditions: Parkinson's Disease
Interventions: TNM Device; Device
Lead sponsor: Scion NeuroStim; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Parkinsonian Syndrome
Interventions: [123I]ß CIT; Drug
Lead sponsor: Institute for Neurodegenerative Disorders; Other
Eligibility: 21 Years and older
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Parkinson's Disease (PD)
Interventions: Not listed
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 427 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 27
States / cities: Birmingham, Alabama • Sun City, Arizona • Palo Alto, California + 24 more

Conditions: Parkinson Disease, Parkinsons Disease With Dementia, Parkinson-Dementia Syndrome, Parkinson Disease 2, Parkinson Disease 3, Parkinson Disease 4
Interventions: No Intervention; Other
Lead sponsor: ProgenaBiome; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 1
States / cities: Ventura, California

Search by objective public record fields.

SIS Evaluation of the MRI Defined Subthalamic Nucleus*

Web-based Genetic Research on Parkinson's Disease

A Study of Brain Imaging With Nuclear Medicine Technology in Individuals With and at Risk for Parkinson's Disease

Study to Assess the Clinical Benefit and Safety of Droxidopa in Parkinson's Disease

Telemedicine Intervention in Patients With Chronic Pain in PD

Pharmacokinetic Study of LY03003 in Patients With Parkinson's Disease

The Microbiome in Parkinson's Disease

Phase IIa Randomized Placebo Controlled Trial: Mesenchymal Stem Cells as a Disease-modifying Therapy for Idiopathic Parkinson's Disease

The Meals Study for Amyotrophic Lateral Sclerosis and Parkinson's Disease

A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD)

Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease.

NINDS Parkinson's Disease Neuroprotection Trial of CoQ10 and GPI 1485

Driving Performance of People With Parkinson's Using Autonomous In-Vehicle Technologies

Bright Light Therapy for Non-motor Symptoms in Parkinson's Disease

ExAblate Transcranial MRgFUS of the Subthalamic Nucleus for Treatment of Parkinson's Disease

Physiological Brain Atlas Development

Davunetide (AL-108) in Predicted Tauopathies - Pilot Study

Singing in Groups for Parkinson's Disease; A Pilot Study of Group Singing Therapy for PD-related Voice/Speech Impairment

Mediterranean Diet Intervention to Improve Gastrointestinal Function in Parkinson's Disease a Randomized, Controlled, Clinical Trial

A Double-blind Study to Evaluate the Safety of Glutamic Acid Decarboxylase Gene Transfer in Parkinson's Participants

A Pilot Study of a Non-Invasive Neuromodulation Device for Treatment of Parkinson's Disease

Study of Individuals With Parkinson's Symptoms But in Whom There is Diagnostic Uncertainty

Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease

A Pilot Study to Explore the Role of Gut Flora in Parkinson's Disease